The angiography-guided spot versus entire stenting in patients with long coronary lesions trial: Study design and rationale for a randomized controlled trial protocol
- Authors
- Baek, Ju Yeol; Rha, Seung Woon; Choi, Byoung Geol; Choi, Cheol Ung; Park, Kyoung-Ha; Hwang, Byung Hee; Lee, Seung-Jin; Ahn, Young Keun; Choi, Jae Woong; Chae, In-Ho; Choi, Won Ho; Lim, Young-Hyo; Ahn, Ji Hoon; Choi, Woong Gil
- Issue Date
- Mar-2020
- Publisher
- ELSEVIER INC
- Keywords
- Spot stenting; Long coronary lesion; Percutaneous coronary intervention
- Citation
- CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, v.17
- Indexed
- SCOPUS
- Journal Title
- CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS
- Volume
- 17
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/57442
- DOI
- 10.1016/j.conctc.2020.100523
- ISSN
- 2451-8654
- Abstract
- Background: /Purpose: Long-stenting, even with a second-generation drug-eluting stent (DES), is an independent predictor of restenosis and stent thrombosis in patients with long coronary lesions. Spot-stenting, i.e., selective stenting of only the most severe stenotic segments of a long lesion, may be an alternative to a DES. The purpose of this study is to compare the one-year clinical outcomes of patients with spot versus entire stenting in long coronary lesions using a second-generation DES. Method: This study is a randomized, prospective, multi-center trial comparing long-term clinical outcomes of angiography-guided spot versus entire stenting in patients with long coronary lesions (>= 25 mm in length). The primary endpoint is target vessel failure (TVF) at 12 months, a composite of cardiac death, target vessel-related myocardial infarction, and target vessel revascularization (TVR). A total of 470 patients are enrolled for this study according to sample size calculations. This study will be conducted to evaluate the non-inferiority of spot stenting compared to entire stenting with zotarolimus-eluting stents (ZES). Results: This study is designed to evaluate the clinical impact of spot-stenting with ZESs for TVF due to possible edge restenosis or non-target lesion revascularization. Theoretically, spot-stenting may decrease the risk of TVR and the extent of endothelial dysfunction. Conclusion: This SPOT trial will provide clinical insight into spot-stenting with a current second-generation DES as a new strategy for long coronary lesions.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
- College of Medicine > Department of Medical Science > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholar.korea.ac.kr/handle/2021.sw.korea/57442)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.